The Abramson Cancer Center facilitates interdisciplinary cancer research, education, and patient care. Its299 members are drawn from 41 Departments and eight Schools of the University and have $120,755,622million in research and training (annual direct costs), a 73% increase in the past five years, of which$111,281,669 is peer-reviewed and $56,709,782 is NCI funded (138% increase in the past five years). Thisincludes 20 NIH P01s and seven P50s. John Glick, MD, has served as Director since 1985. ElevenResearch Programs comprise the Cancer Center's three Divisions (Fundamental Research, ClinicalResearch, Cancer Control and Population Sciences). The Cancer Center supports 15 Shared Resources,five of which are new. The development of strong Research Programs and leading-edge Shared Resources,the recruitment of outstanding faculty in areas of priority, and the acquisition of additional research spacehave enabled the Cancer Center to realize its mission. An ongoing strategic planning process identifiesfuture directions, while guiding current activities and resource allocations. A wide range of seminars andretreats as well as interdisciplinary laboratory space are among the ways in which the Cancer Centersucessfully facilitates interaction and collaboration. Developmental Funds are critical to faculty recruitmentand the funding of innovative pilot projects with the potential for peer-reviewed funding, translationalresearch initiatives, and Shared Resources. The Division of Cancer Control and Population Sciences hasbenefited from the recruitment of Caryn Lerman, PhD, as Associate Director and other significant facultyrecruitments. The Clinical Research Division's progress is distinguished by innovative translational researchin all Research Programs and a nationally recognized experimental therapeutics effort. In the basic sciences,leadership changes have led to greater activity in translational research and increased collaborations. TheCancer Center continues to meet Comprehensiveness guidelines, and was last approved in 1999.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016520-33S2
Application #
7683575
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-01-15
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$250,000
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32

Showing the most recent 10 out of 1047 publications